Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.61 |
| ▸ | NPC1 | O15118 | 6/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.61 |
| ▸ | RELA | Q04206 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | PLAU | P00749 | 1/20 | 0.54 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.53 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.53 |
| ▸ | MELK | Q14680 | 2/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30847429 | 1.00 | RAB9A (0.61) | RAB9ANPC1TP53GAANFKB1 | |
| SCHEMBL6984836 | 0.92 | RAB9A (0.66) | RAB9ANPC1TP53GAANFKB1 | |
| SCHEMBL4717947 | 0.85 | KCNK3 (0.56) | RAB9ANPC1TP53SMN1; SMN2PLAU | |
| SCHEMBL10365448 | 0.82 | MAP4K1 (0.65) | RAB9ANPC1TP53GAANFKB1 | |
| SCHEMBL27370339 | 0.80 | NPC1 (0.64) | RAB9ANPC1GAAMAPK14TMPRSS2 | |
| SCHEMBL30718462 | 0.80 | NPC1 (0.64) | RAB9ANPC1GAAMAPK14TMPRSS2 | |
| SCHEMBL31488089 | 0.79 | NPC1 (0.51) | RAB9ANPC1HTTSMN1; SMN2PLAU | |
| SCHEMBL880654 | 0.79 | NPC1 (0.51) | RAB9ANPC1HTTSMN1; SMN2PLAU | |
| SCHEMBL29642942 | 0.79 | PLAU (0.52) | NPC1PLAUMELKCA12CA2 | |
| SCHEMBL8197860 | 0.79 | MELK (0.68) | RAB9ANPC1TP53GAANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024006956-A9 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024006956-A9 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024006956-A2 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| CN-101309904-A | 1- (1H-indol-1-yl) -3- (methylamino) -1-phenylpropan-2-ol derivatives and related compounds as monoamine reuptake modulators for the treatment of vasomotor symptoms (VMS) | WYETH CORP (US) | 2008-11-19 | — | — | CN | disclosed |
| EP-1931631-A1 | 1- (1H- INDOL- 1-YL) -3- (METHYLAMINO) -1- PHENYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | Wyeth a Corporation of the State of Delaware (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007041023-A1 | 1- (1H- INDOL- 1-YL) -3- (METHYLAMINO) -1- PHENYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072897-A1 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072897-A1 | Phenylaminopropanol derivatives and methods of their use | COMT, PNMT, GLS | RAB9A 2205/4885NPC1 2982/4885TP53 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.